lecozotan

Small moleculeexperimental

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients. As of June 2008, the first Phase III clinical trial has been completed. — Wikipedia

Clinical trial activity

8 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Feb 1, 2005 (NCT00151333)

Timeline

2000s

Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Jan 1, 2006
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Serotonin 1a (5-HT1a) receptorANTAGONIST
HTR1A antagonist
Not in current pipeline
- 5-hydroxytryptamine receptor 1A (HTR1A) ↗

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](CN(C(=O)c1ccc(C#N)cc1)c1ccccn1)N1CCN(c2cccc3c2OCCO3)CC1

Mol. weight: 483.57 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

lecozotan
lecozotan
lecozotan
lecozotan
lecozotan hcl
lecozotan hcl
lecozotan hydrochloride
lecozotan hydrochloride
sra-333
sra-333
sra-333

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00563732	Phase 1	Dec 1, 2007	Pfizer, Wyeth
NCT00538889	Phase 1	Aug 1, 2007	Pfizer, Wyeth
NCT00494962	Phase 1	Jun 1, 2007	Pfizer, Wyeth
NCT00499642	Phase 1	Jun 1, 2007	Pfizer, Wyeth
NCT00366483	Phase 1	May 1, 2006	Pfizer, Wyeth
NCT00277810	Phase 2/Phase 3 (Phase 3)	Mar 1, 2006	Pfizer, Wyeth
NCT00151398	Phase 2	Sep 1, 2005	Pfizer, Wyeth
NCT00151333	Phase 2	Feb 1, 2005	Pfizer, Wyeth

Showing 8 of 8 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Pfizer	For profit	8	8	3	2005
Wyeth	For profit	8	0	3	2005

2 organizations

Page 1 / 1